ClinicalTrials.gg
Not yet recruitingNCT07625722Updated Jun 4, 2026

Thyroxine Supplementation in Small for Gestational Age (SGA) Infants With Birth Weight <1500g and TSH 6-20 mIU/ml

An interventional study of Levothyroxine Sodium (LT4) Tablets in Thyroid Function, Preterm and SGA and Growth, sponsored by Shandong Provincial Hospital. Not yet recruiting at 1 site in China. Open to participants aged 2 Weeks to 2 Weeks. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Shandong Provincial Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
2 Weeks to 2 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Premature Birth with a site in China — 26 open to participants now, 31 under way, 2 of them phase 3. Premature Birth · China.

Planned enrollment
33rd of 44
106 · median 195
Started
2026
with 9 others
No phase
25 of 79
8 open now
Primary completion
2027-06
later than 18 of 30 live
Registered
75th of 79
by date

Among the 79 studies in Premature Birth with a site in China, this one is the 33rd largest by planned enrollment of the 44 interventional ones that give a count, is one of 10 that started in 2026, is one of 25 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 75th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

26 of the 79 studies in Premature Birth with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 2 Weeks to 2 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Premature Birth with a site in China, or all of them as a file.
02

Study summary

The primary objective of this clinical trail is to evaluate whether early supplementation of levothyroxine (L-T4) at a dosage of 8 ug/kg/d, initiated in the second week of life, improves physical growth and neurodevelopmental outcomes at 2 years of corrected age in Small for Gestational Age (SGA) infants with birth weights \< 1500g and TSH levels between 6 and 20 mIU/ml. Preterm infants in the intervention group will receive 8 ug/kg/d of L-T4, while the control group will receive no supplementation. Physical growth will be assessed through height, weight, and head circumference, while neurodevelopmental status will be evaluated using the Bayley-IV scales and cranial MRI imaging findings.

03

Conditions studied

  • Thyroid Function
  • Preterm
  • SGA and Growth
  • Neurodevelopment Outcome

Browse trials for

04

Who can participate

Ages eligible
2 Weeks to 2 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants born Small for Gestational Age (SGA) with a birth weight \< 1500g;
  • Admitted to a participating Neonatal Intensive Care Unit (NICU) within 7 days of birth;
  • Serum concentrations of TSH, FT4, and FT3 are measured weekly during the first and second weeks of life,any single TSH measurement during this period is between 6 and 20 mIU/mL;
  • Written obtained from the parents.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Congenital Hypothyroidism (CH) with serum TSH > 20 mIU/mL within the first 2 weeks of life and receiving L-T4 treatment;
  • Persistent serum TSH \< 6 mIU/mL throughout the first 2 weeks;
  • Elevated thyroid hormone levels(T3, T4, FT3, or FT4) above the reference range within the first 2 weeks;
  • Diagnosis of Grade III or IV Intraventricular Hemorrhage (IVH) within the first 2 weeks of life;
  • Presence of major congenital malformations of vital organs or known chromosomal/genetic disorders;
  • History of maternal thyroid disease or maternal use of thyroid-related medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • No intervention
    control group
  • Experimental
    intervention group

    Drug: Levothyroxine Sodium (LT4) Tablets

Interventions

  • DrugThyroxineStudies of ThyroxineThyroxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention group will receive oral levothyroxine (L-T4) initiated on postnatal day 14 at a starting dose of 8 ug/kg/day. Thyroid function will be monitored every 2-4 weeks until 36 weeks postmenstrual age or hospital discharge, with subsequent follow-up at corrected ages of 40 weeks, 3, 6, 12, 18, and 24 months. The L-T4 dosage will be dynamically titrated to achieve therapeutic targets of TSH \< 5 mIU/L and FT3/FT4 levels within the upper 50% of the age-specific reference range. Treatment will be discontinued if therapeutic targets are sustained at a dosage below 2 ug/kg/day or if FT3/FT4 levels exceed the upper limit of normal.

06

What researchers measure

Primary outcomes

  1. Cognitive function evaluated by Bayley-IV

    Time frame: At 24 months corrected age

  2. Motor function evaluated by Bayley-IV

    Time frame: At 24 months corrected age

  3. Language function evaluated by Bayley-IV

    Time frame: At 24 months corrected age

  4. Social-Emotional evaluated by Bayley-IV

    Time frame: At 24 months corrected age

  5. Adaptive behavior evaluated by Bayley-IV

    Time frame: At 24 months corrected age

  6. Body length(cm)assessed by the WHO 0-5 years Child Growth Standards.

    Time frame: At 24 months corrected age

  7. Head circumference(cm)assessed by the WHO 0-5 years Child Growth Standards.

    Time frame: At 24 months corrected age

  8. Weight(kg)assessed by the WHO 0-5 years Child Growth Standards.

    Time frame: At 24 months corrected age

Secondary outcomes

  1. the incidence of neonatal morbidities (EUGR、PNAC、MBDP、Moderate to severe BPD、Stage III or higher ROP)during the initial hospitalization

    Time frame: at 36 weeks of postmenstrual age

  2. All-cause Mortality

    Time frame: At 24 months corrected age

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Jun 4, 2026
StartEst.
Jun 20, 2026
Primary completionEst.
Jun 20, 2027
CompletionEst.
Jun 20, 2029
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07625722
Lead sponsor
Shandong Provincial Hospital
Responsible party
Yonghui Yu (Chief physician, Shandong Provincial Hospital) — Principal investigator
First posted
Jun 4, 2026
Start date
Jun 20, 2026 (estimated)
Primary completion
Jun 20, 2027 (estimated)
Completion
Jun 20, 2029 (estimated)
Last update
Jun 4, 2026

Study contacts

Yonghui Yu
Contact
alice20402@126.com
+8615168887236

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thyroxine

Start the discussion